论文部分内容阅读
支气管哮喘患者１０１例，随机双盲分为２组，沙美特罗组５２例（男性３４例，女性１８例；年龄３８±ｓ１０ａ），吸入沙美特罗５０μｇ，ｂｉｄ；相似患者４９例（男性３０例，女性１９例；年龄３８±９ａ），吸入沙丁胺醇２００μｇ，ｑｉｄ。２组治疗均４ｗｋ。结果显示沙美特罗组晨起最大呼气流速（ＰＥＦＲ）有显著改善（由２９６±８９Ｌ／ｍｉｎ增至３２１±１０２Ｌ／ｍｉｎ），提示沙美特罗作用时间较长，有助于对夜间哮喘的治疗。
One hundred and eleven patients with bronchial asthma were randomly divided into two groups with randomized double-blind treatment. Salmeterol group included 52 patients (34 males and 18 females; age 38 ± s10a), salmeterol 50 μg bid, and 49 similar patients (30 males Cases, 19 females; age 38 ± 9a), inhaled salbutamol 200μg, qid. 2 groups were treated 4wk. The results showed that the maximum expiratory flow rate (PEFR) improved significantly from 296 ± 89 L / min to 321 ± 102 L / min in the salmeterol group, suggesting that salmeterol has a longer duration of action and may be of benefit to nighttime asthma treatment.